Cargando…
Review: Mechanotransduction in ovarian cancer: Shearing into the unknown
Ovarian cancer remains a deadly diagnosis with an 85% recurrence rate and a 5-year survival rate of only 46%. The poor outlook of this disease has improved little over the past 50 years owing to the lack of early detection, chemoresistance and the complex tumor microenvironment. Within the peritonea...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AIP Publishing LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481715/ https://www.ncbi.nlm.nih.gov/pubmed/31069311 http://dx.doi.org/10.1063/1.5024386 |
_version_ | 1783413780233846784 |
---|---|
author | Novak, Caymen Horst, Eric Mehta, Geeta |
author_facet | Novak, Caymen Horst, Eric Mehta, Geeta |
author_sort | Novak, Caymen |
collection | PubMed |
description | Ovarian cancer remains a deadly diagnosis with an 85% recurrence rate and a 5-year survival rate of only 46%. The poor outlook of this disease has improved little over the past 50 years owing to the lack of early detection, chemoresistance and the complex tumor microenvironment. Within the peritoneal cavity, the presence of ascites stimulates ovarian tumors with shear stresses. The stiff environment found within the tumor extracellular matrix and the peritoneal membrane are also implicated in the metastatic potential and epithelial to mesenchymal transition (EMT) of ovarian cancer. Though these mechanical cues remain highly relevant to the understanding and treatment of ovarian cancers, our current knowledge of their biological processes and their clinical relevance is deeply lacking. Seminal studies on ovarian cancer mechanotransduction have demonstrated close ties between mechanotransduction and ovarian cancer chemoresistance, EMT, enhanced cancer stem cell populations, and metastasis. This review summarizes our current understanding of ovarian cancer mechanotransduction and the gaps in knowledge that exist. Future investigations on ovarian cancer mechanotransduction will greatly improve clinical outcomes via systematic studies that determine shear stress magnitude and its influence on ovarian cancer progression, metastasis, and treatment. |
format | Online Article Text |
id | pubmed-6481715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | AIP Publishing LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-64817152019-05-08 Review: Mechanotransduction in ovarian cancer: Shearing into the unknown Novak, Caymen Horst, Eric Mehta, Geeta APL Bioeng Special Topic: Bioengineering of Cancer Ovarian cancer remains a deadly diagnosis with an 85% recurrence rate and a 5-year survival rate of only 46%. The poor outlook of this disease has improved little over the past 50 years owing to the lack of early detection, chemoresistance and the complex tumor microenvironment. Within the peritoneal cavity, the presence of ascites stimulates ovarian tumors with shear stresses. The stiff environment found within the tumor extracellular matrix and the peritoneal membrane are also implicated in the metastatic potential and epithelial to mesenchymal transition (EMT) of ovarian cancer. Though these mechanical cues remain highly relevant to the understanding and treatment of ovarian cancers, our current knowledge of their biological processes and their clinical relevance is deeply lacking. Seminal studies on ovarian cancer mechanotransduction have demonstrated close ties between mechanotransduction and ovarian cancer chemoresistance, EMT, enhanced cancer stem cell populations, and metastasis. This review summarizes our current understanding of ovarian cancer mechanotransduction and the gaps in knowledge that exist. Future investigations on ovarian cancer mechanotransduction will greatly improve clinical outcomes via systematic studies that determine shear stress magnitude and its influence on ovarian cancer progression, metastasis, and treatment. AIP Publishing LLC 2018-06-07 /pmc/articles/PMC6481715/ /pubmed/31069311 http://dx.doi.org/10.1063/1.5024386 Text en © 2018 Author(s). 2473-2877/2018/2(3)/000000/17 All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Special Topic: Bioengineering of Cancer Novak, Caymen Horst, Eric Mehta, Geeta Review: Mechanotransduction in ovarian cancer: Shearing into the unknown |
title | Review: Mechanotransduction in ovarian cancer: Shearing into the
unknown |
title_full | Review: Mechanotransduction in ovarian cancer: Shearing into the
unknown |
title_fullStr | Review: Mechanotransduction in ovarian cancer: Shearing into the
unknown |
title_full_unstemmed | Review: Mechanotransduction in ovarian cancer: Shearing into the
unknown |
title_short | Review: Mechanotransduction in ovarian cancer: Shearing into the
unknown |
title_sort | review: mechanotransduction in ovarian cancer: shearing into the
unknown |
topic | Special Topic: Bioengineering of Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481715/ https://www.ncbi.nlm.nih.gov/pubmed/31069311 http://dx.doi.org/10.1063/1.5024386 |
work_keys_str_mv | AT novakcaymen reviewmechanotransductioninovariancancershearingintotheunknown AT horsteric reviewmechanotransductioninovariancancershearingintotheunknown AT mehtageeta reviewmechanotransductioninovariancancershearingintotheunknown |